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Abstract: Endemic Burkitt lymphoma (BL) was publically described in 1958 and remains the 
most prevalent pediatric cancer in equatorial Africa with an annual incidence between two and 
five cases per 100,000 children. Several risk factors have been identified, including early-age 
infection with Epstein–Barr virus, a geographic association with high Plasmodium falciparum 
malaria transmission, and poor nutrition. However, other modifiable factors play a role in 
the survival of these children. Treatment regimens for BL have evolved over a time period 
that spans nearly 50 years. This review will compare survival between different combination 
chemotherapeutic regimens and discuss other key determinants of outcomes among children 
diagnosed with BL in resource-limited settings. A discussion of obstacles to diagnosis will be 
presented, including low community awareness of pediatric cancer, limited access to health 
facilities, inaccurate or delayed diagnosis often beginning at lower level health rural facilities 
that are typically staffed by those with limited training in oncology, and insufficient pathology 
support to confirm diagnosis. Other challenges examined here include those related to treatment 
adherence, specifically the social and economic stressors that can lead to abandonment of care, 
and treatment-related toxicity, a challenge compounded not only by the scarcity of medications 
for supportive care, but also the paucity of clinically trained medical professionals available to 
manage integrated care for these children. Future directions for enhancing BL survival will be 
discussed including molecular approaches for rational drug discovery as well as the benefits of 
forming a unified, global BL research network.
Keywords: pediatric cancer, treatment regimen, Africa, social and economic predictors, 
biomarkers
Introduction
Burkitt lymphoma (BL) is a mature B-cell neoplasm of the lymphatic system that was 
publically described in 1958 by a surgeon named Denis Burkitt who was working 
in equatorial Africa at the time.1 He documented a clinical entity that characteristi-
cally affects the jaw or other facial bones of young children.1 It is now known that 
BL also affects other sites, including the abdomen (lymph nodes, spleen, kidneys, 
liver, ovaries), extradural space of the spinal canal (often presenting as paraplegia), 
bone marrow, and central nervous system. One of the key clinical characteristics of 
BL is that it rapidly progresses and can double in size within 48 hours, and therefore 
requires urgent evaluation and treatment.2 However, the rapid doubling time of these 
tumor cells make them exquisitely responsive to chemotherapy without the need for 
radiotherapy or surgery. This also makes this cancer imminently curable in resource-
limited settings where it is most prevalent.
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BL is widely reported to be the most common pediatric 
cancer in Africa.3,4 The average annual incidence of endemic 
BL (eBL) is two cases per 100,000 children, which is 20-fold 
higher than sporadic BL in the US.3,5 The median onset age 
of eBL is 6 years (ranging from 2–14 years of age)6 and 
coinfections with Epstein–Barr virus (EBV) and Plasmodium 
falciparum malaria early in life have been identified as risk 
factors in the development of this pediatric cancer (reviewed 
in Moormann et al).7
Despite over 50 years of intensive clinical study and epi-
demiologic research, BL remains the most prevalent pediatric 
cancer in equatorial Africa and survival rates for children 
receiving treatment remain far below those in high-income 
countries. Improving outcomes in this setting requires a 
greater understanding of both how to deliver the chemothera-
peutic armamentarium at hand and ways to apply evidence 
based medical practice for evaluating new chemotherapies. 
Additionally, there is a need to more broadly and effectively 
address many of the unique challenges of managing cancer 
therapy in resource-limited settings, which includes not just 
the medical aspects of diagnosis and treatment, but also the 
social and economic considerations that can lead to poor 
outcomes, largely through abandonment of care. This review 
goes beyond the bedside to describe other factors critical 
to achieving the optimal management of BL and how they 
could be implemented.
Epidemiology and etiology
BL was the first human cancer demonstrated to harbor a 
virus.8 This discovery by Anthony Epstein, Yvonne Barr, and 
Bert Achong led to implicating EBV and other viruses in the 
etiology of human cancers. Since its discovery, the under-
standing of EBV persistence, pathogenesis, and immune 
evasion that facilitate the development of malignant B-cells 
has made great strides even if the precise mechanisms have 
yet to be fully realized. The roles of EBV gene products 
and the c-myc translocation in BL pathogenesis have been 
reviewed in detail elsewhere.9
BL was also the first human cancer geographically mapped 
by its incidence. In 1961, Denis Burkitt, Ted Williams, and 
Cliff Nelson were able to localize BL incidence in Africa to 
the lymphoma belt that straddles the equator by 15 degrees 
to the north and south.10,11 This observation led Alexander 
Haddow to speculate that a mosquito vector might be involved 
in eBL etiology,12 which prompted Gilbert Dalldorf in 1964 
to hone in on intense P. falciparum malaria transmission 
as a risk factor for eBL.13 The geographic overlay between 
high malaria transmission and incidence of eBL has been 
previously described14,15 and validated by others;16,17 however, 
the precise mechanisms by which malaria contributes to eBL 
pathogenesis remain speculative and are reviewed in more 
detail by Moormann et al.7
In brief, early studies suggested that malaria impaired 
T-cell control over EBV-infected B-cells18,19 and also induced 
lytic reactivation.20 Over the past 40 years, it has become 
possible to appreciate the complexity of human immune 
responses to infectious diseases and the necessity of longi-
tudinal infant cohort studies to demystify the sequence and 
magnitude of events that result in inefficient immunity to 
EBV.7 The working hypothesis for eBL etiology is two-fold 
and synergistic. In populations where eBL is prevalent, nearly 
all children experience their primary EBV infection before 
1 year of age.21 This suggests that maternal antibodies are not 
effectively protecting infants from early-age EBV infections. 
This time period also spans the age at which children are most 
susceptible to malaria if maternal antibodies are insufficiently 
protective. In malaria holoendemic areas, children can experi-
ence two to three malaria infections during the first year of 
life, but after cumulative infections children develop partially 
protective immunity that allows them to harbor asymptomatic 
infections.22 This immunologic tolerance allows the sustained 
interaction between malaria and EBV within the human host 
with evidence of T-cell exhaustion (Moormann, unpublished 
data, 2013) after this prolonged attempt to balance immune 
control over viral pathogenesis.
Understanding precisely how these two ubiquitous child-
hood infections lead to oncogenesis is foreseeable, provided 
investments are made in robust epidemiologic studies that are 
designed with the appropriate control group comparisons to 
answer these questions. Conclusions about the role of malaria 
in eBL etiology can only be made when controls are matched 
to cases by variables that impact malaria exposure and 
resulting immunity. These variables include geography and 
chronology, which control for malaria transmission intensity 
and parasite genetic diversity, and ethnicity and age, which 
may influence immunity to both malaria and EBV. Challenges 
would nevertheless remain as to how to prevent these com-
mon childhood infections in the endemic setting and thereby 
prevent eBL. In addition, the possibility remains that even 
with malaria control, BL could remain incident. Other cofac-
tors may replace malaria as the immune modulating event 
given EBV is the initiator of tumorigenesis. Prior studies have 
explored the role of nutritional deficiencies,23 arboviral infec-
tions as other risk factors,24 and human immunodeficiency 
virus (HIV), particularly in the setting of a growing genera-
tion of HIV-infected infants25 who are surviving longer on 
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Optimal treatment for eBL
antiretroviral therapy. Immunodeficiency-associated BL has 
been documented for adult HIV patients,26 and children who 
are HIV infected and present with BL have a worse prognosis 
compared to those who do not have HIV.27,28 There is also the 
possibility that age of primary EBV infection might naturally 
shift to an older age group with improving socioeconomic 
conditions in developing countries. The changing epidemiol-
ogy of EBV has been recently demonstrated in populations 
within the US29,30 and discussions are currently underway on 
the feasibility of testing a prophylactic EBV vaccine.31 The 
authors speculate that the global roll out of malaria control 
programs and improvements in infrastructure may explain the 
gradual decrease in eBL incidence observed at the Jaramogi 
Oginga Odinga Teaching and Referral Hospital in Kisumu, 
Kenya over the past 7 years. Western Kenya is the catchment 
area for this regional cancer referral hospital, and also the area 
where the Kenya Medical Research Institute, in collaboration 
with the US Centers for Disease Control and Prevention, 
conducted the original insecticide-treated bed net trials that 
demonstrated sustained reductions in malaria transmission.32 
Unfortunately, malaria may be resurging due to changes in 
vector behaviors33 and mosquito resistance to permethrin that 
is used to impregnate the bed nets.34
Diagnosis
The challenges in diagnosing cancers in low-income set-
tings are many and multifactorial. Community awareness of 
cancer in these settings is often limited.35 Many patients who 
have characteristic findings of BL (eg, jaw mass, distended 
abdomen, fevers, weight loss, night sweats) will initially 
be evaluated by an herbalist, traditional healer, or by prac-
titioners in a rural clinic setting who may not consider the 
possibility of a cancer diagnosis.36 Consequently, precious 
time can be wasted with various treatments that are ultimately 
futile, resulting in delays in necessary medical consultation, 
diagnostic evaluation, and initiation of appropriate treatment. 
Furthermore, as in most settings, access to health services 
remains limited among the poorest populations. Even when 
a cancer diagnosis is recognized and referred immediately, 
economic barriers and lack of transportation to an equipped 
tertiary facility may delay further evaluation by weeks or 
even months.
Once a child has been appropriately referred and evaluated 
at a tertiary care level facility, there are still several barriers 
that must be overcome to make a definitive diagnosis of BL. 
Although the clinical presentation of BL has characteristic 
clues that may lead to a high clinical suspicion of BL, making 
a tissue-based histopathological diagnosis is critical to both 
ensure accurate diagnosis (to exclude other primary tumors) 
and inform decisions regarding appropriate treatment. In 
settings with plentiful resources, the diagnosis of BL is con-
firmed with a multimodal approach of histopathology, includ-
ing immunohistochemistry on a tissue specimen obtained by 
biopsy (incision, excisional, or core), flow cytometry, and 
cytogenetics. Unfortunately, this combination of technology 
and resources rarely exists in resource-limited settings. In 
the unlikely scenario that they do exist, the turnaround time 
for diagnosis (estimates of 7–10 days) palpably lags in the 
race to treat rapidly growing tumors such as BL. Not only do 
resource-limited settings often lack the technology to carry 
out necessary diagnostics, but the lack of personnel trained 
in these modalities and logistical limitations, such as access 
to a surgical theater or appropriate anesthesia to obtain a 
biopsy specimen, abound as well.35
Consequently, the diagnosis of BL is often based 
solely on the child’s clinical presentation and may or may 
not include fine-needle aspiration biopsy with cytologic 
examination. Fine-needle aspiration biopsy is a diagnostic 
modality that offers relatively rapid results, often available 
within 24–48 hours; however, its accuracy is not optimal. 
A recent multi-institutional assessment of fine-needle 
aspiration biopsy for childhood cancers in resource-limited 
settings demonstrated a 96.4% diagnostic accuracy for non-
Hodgkin’s lymphoma, with 87.5% (14/16 cases) accurately 
diagnosed as BL.37 Unfortunately, this approach may lead 
to misdiagnosis in some children, which can have devastat-
ing implications, all too often leading to poor outcomes 
in a disease that would otherwise be curable. Some have 
advocated for an Internet-based telemedicine approach 
for pathologic consultation to address the need for trained 
pathologists; however, lack of reliable internet resources and 
costs associated with implementing this technology have 
prohibited widespread adoption. Optimism is being renewed 
with decreasing costs of mobile devices such as open-source 
tablets and cell phones, which are now being used to store 
and send digital images for remote consultations and for 
educational training purposes with other forms of cancer.38 In 
addition, concerted efforts to develop and strengthen national 
cancer registries in sub-Saharan countries have arisen, par-
ticularly pertaining to HIV and acquired immunodeficiency 
syndrome-related cancers.39
Following a proper diagnosis of BL, every child should 
also undergo staging of the tumor in order to accurately assess 
the extent of disease. In resource-rich settings, disease extent 
informs treatment decisions such that more advanced tumors 
are treated more aggressively and less advanced tumors require 
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less intensive treatment. Ideally, disease staging should 
include chest X-ray to assess for mediastinal involvement 
and/or the presence of pleural effusion, abdominal ultrasound 
to evaluate for intraabdominal lymphadenopathy and/or orga-
nomegaly, bone marrow aspiration and biopsy to evaluate for 
malignant infiltration of the bone marrow space, and a spinal 
tap with cerebrospinal fluid cytology to assess for evidence 
of central nervous system involvement. Again, due to lack 
of resources and trained personnel and logistical limita-
tions, this staging evaluation is rarely undertaken or is often 
incomplete or imprecise in most resource-limited settings. 
Without full information on staging, many children with BL 
in resource-limited settings are treated with a standardized 
one-size-fits-all protocol without consideration of risk factors, 
including extent of disease. Thus, children may receive more 
or less aggressive therapy than their disease would otherwise 
mandate if they were being treated in a high-income setting. 
Alternatively, a lower induction dose of chemotherapy may 
be prescribed for children with larger palpable tumors in an 
attempt to mitigate tumor lysis syndrome. While these prac-
tices may initially appear substandard, this approach has its 
merits in settings where treatment options and supportive care 
measures are less sophisticated. Moreover, prognostic factors 
that have been validated in high-income countries may have 
reduced predictive value in low-income countries where most 
patients have advanced disease due to late presentation, and 
other comorbidities, including malnutrition and infections, 
are abundant.4 There is clearly a need to discover predic-
tive and prognostic biomarkers for BL that could be readily 
measured from serum samples and used to guide treatment. 
Lactate dehydrogenase (LDH) has been used as a nonspecific 
surrogate of tumor burden; however, serum LDH40 may be 
suboptimal in settings where children experience malaria 
coinfections that are independently associated with elevated 
LDH levels.41 Discovering biomarkers with high sensitivity 
and specificity for eBL would enable a rational approach 
for identifying which children to put “on trial”42 and those 
who may do just fine using the conventional, less intensive 
treatment.
History of treatment regimens  
and patient survival
BL is a rare example of pediatric cancer that can be cured 
with a short course or even single dose of cyclophosphamide. 
Multiple studies reported in the 1960s and 1970s showed sur-
vival rates of 6%–38% for large numbers of African children 
with eBL.43–52 Based on those early findings and the concerns 
for increased toxicity with combination chemotherapy, 
treatment for BL in Africa has remained unchanged for many 
years. After reports of improved survival in limited-stage 
disease in children treated with combination chemotherapy, 
including cyclophosphamide, vincristine, methotrexate, and 
prednisone (COMP), on a North American Children’s Cancer 
Group (CCG) trial, CCG-551,53 and marked improvement in 
outcomes for children with both limited- and advanced-stage 
BL treated with combination chemotherapy on the lymphoma 
malignancy B-cell (LMB) trials,54 new treatment protocols 
were introduced in Africa. Reports from ten trials published 
since 2000 are summarized in Table 1.
The underlying question “what is the optimal treatment 
for eBL?” is difficult to answer based on underlying differ-
ences between studies. Issues limiting a meta-analysis include 
patient selection bias, different inclusion and exclusion 
criteria, adequacy of diagnosis and staging, varying levels 
of treatment adherence, differences in outcomes reported, 
and adequacy of reporting of study methodology. What is 
apparent from Table 1 is that there is a trend toward improved 
survival with increasing intensity of treatment. Single agent 
trials achieved 30%–50% survival, while studies using 
COMP as the backbone of treatment reported survival rates 
of 50%–70%. Centers able to administer treatment most 
similar to the LMB intermediate risk therapy with doxoru-
bicin, higher dose methotrexate, and cytarabine had survival 
rates of 75%–80%. The authors’ experience in Eldoret, 
Kenya within the Academic Model for Providing Access 
to Healthcare (AMPATH) program over the past 4 years 
delivering therapy including doxorubicin and cytarabine on 
a backbone of COMP therapy mirrors that overall outcome. 
The authors’ experience in Kisumu at the Jaramogi Oginga 
Odinga Teaching and Referral Hospital using COMP over 
the past 10 years had survival rates of 67%. While more 
intensified treatments have led to improved outcomes, the 
role of robust ancillary care such as antibiotics, nutritional 
support, and blood products cannot be overemphasized. 
Previous efforts to introduce high-dose intensive treat-
ment protocols with limited supportive care resources have 
resulted in unacceptably high treatment- related morbidity 
and mortality.55 Unfortunately, many centers have inadequate 
infrastructure and limited capacity to deliver this care. Both 
areas must be strengthened in order to administer intensive 
therapy for BL tumors that are advanced stage at diagnosis 
or refractory to conventional therapy. To attain survival rates 
similar to those in high-income countries, concerted effort 
will be needed to focus on improving not only the infrastruc-
ture, but also the knowledge base of medical practitioners 
throughout the health system, including lower level health 
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Table 1 Dose intensity of chemotherapeutic agents used in ten protocols of treatment for Burkitt lymphoma in Africa reported since 
2000
Chemotherapy dose intensity (mg/m2/week)
Study  
type
Citation (first 
author, year)
Cyclophosphamide Prednisone Vincristine Methotrexate Cytarabine Doxorubicin IT  
meds
Survival Patients
Single Kazembe,65 2003 600 No 43% 92
agent Traore,66 2011 1,200 Yes 33% 178
Hesseling,67 2009 600–1,200 Yes 48% 40
COMP Koffi,68 2010 1,200 30 250 Yes 62% 85
Ngoma,69 2012 600 0.7 37.5 Yes 62% 356
Hesseling,70 2005 250 210 1 1,000 Yes 33% 42
Hesseling,55 2003 250 210 1 1,000 200 Yes 59% 44
Davidson,71 2010 300 75 0.75 75 Yes 72% 29
Hesseling,72 2012 1,200 0.5 333 Yes 61% 129
Traore,66 2011 500 100 0.67 1,000 Yes 50% 76
Harif,73 2008 500 100 0.67 1,000 Yes 56% 187
or 1,000 167
LMB Harif,73 2008 500 100 0.67 1,000 20 Yes 75% 119
1,000 167
333 100 0.67 20
Davidson,71 2006 500 100 0.75 1,000 20 Yes 81% 63
1,000 167
333 100 0.67 20
Note: Study types include single agent cyclophosphamide studies, studies using COMP53 as the backbone of therapy, or those using variations the French LMB8954 studies 
with doxorubicin. Doses displayed are for the agents used in the first 4 months of the protocols. The last three studies alternated cycles of chemotherapy, using two or three 
different combinations of chemotherapy. Use of intrathecal medications (IT) is indicated. Survival percentage as shown is based the number of patients enrolled in the final 
column. Survival time varied studies with doxorubicin. Survival time was reported at one to five years of follow-up.
Abbreviations: COMP, cyclophosphamide, vincristine, methotrexate, and prednisone; LMB, lymphoma malignancy B-cell; meds, medications.
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facilities, and establishing government sponsored support 
systems that include oncology and other chronic diseases. 
The authors are working to improve the infrastructure in 
their treatment centers in Kenya with the goal of safely and 
effectively delivering chemotherapy regimens shown to be 
most successful in high-income countries. However, since BL 
is after all a relatively rare disease, the formation of a global 
BL clinical trial network with standardized treatment proto-
cols and level of care across hospitals would offer a platform 
upon which there could be a collective effort to advance the 
understanding of optimal therapeutic strategies. This would 
include efforts to empirically identify molecular pathways 
that lend themselves to rationally targeted chemotherapies 
with treatment trials that could prospectively determine if 
eBL survival is improved and relapse prevented.
Factors that influence treatment 
outcomes: from socioeconomic 
factors to host genetics
Beyond disease burden and selection of treatment protocols, 
there are multiple other factors that may influence treatment 
outcomes for eBL, ranging from socioeconomic factors to 
host genetics. These influences are important to consider, 
particularly in the absence of prognostic markers of response 
and survival validated for eBL in resource-limited settings. 
While prognostic markers of disease response and survival 
have been well established for non-Hodgkin’s lymphoma in 
high-income settings (eg, tumor stage, serum LDH levels, 
presence or absence of central nervous system involvement),56 
there are unfortunately more questions than answers when it 
comes to prognostic indicators for eBL.
It has been well established that the socioeconomic 
status of a child’s family can have a profound impact on the 
choice to initiate treatment and/or adhere to prescribed care, 
particularly in low-income countries where abandonment 
of care is a common problem.57 The cost of chemotherapy 
alone is prohibitively expensive for most families in low-
income countries but the availability of national hospital 
insurance can improve patient retention.58 Additionally, 
because resource-constrained settings have relatively few 
treatment centers that are equipped to treat children with 
cancer, it is not uncommon for families to endure long 
(and expensive) commutes to receive therapy. These costs 
are often compounded during the child’s in-hospital treat-
ment as families experience losses in daily income while 
caregivers stay with their child, often for weeks or even 
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months at a time. Together, these factors present significant 
barriers to care for families who are already struggling to 
make ends meet and the authors dream of a day when they 
could provide a subsidized place for families of hospitalized 
children to stay.
Host factors that are independent of tumor biology 
itself also play a role. Many children in resource-limited 
settings are malnourished even prior to a cancer diagnosis. 
The importance of nutritional status in children with cancer 
cannot be understated. Malnutrition has many effects on 
treatment, including decreased tolerance of chemotherapy, 
altered metabolism of antineoplastic drugs, increased infec-
tion rates, and poor clinical outcomes.59 Maintaining adequate 
nutrition throughout the course of treatment has been shown 
to have a positive impact on the risk of relapse and overall 
survival.60–63
Continuing to improve the survival of children with BL 
across Africa and other resource-limited settings will also 
require solutions that reach beyond the bedside. Studies offer-
ing social support for the child and family member caring 
for the child have shown significantly improved treatment 
adherence. This has included reimbursements for travel, lodg-
ing, and food, and, in some cases, partial or full subsidization 
of medical care, which further decreases the financial burden 
experienced by the family. If social support is available, 
a careful assessment of the family’s resources should begin 
early, if not concomitantly with diagnostic evaluations. In 
Kenya, the authors have found that hiring a Case Manager 
(also referred to as a Patient Navigator) can alleviate some 
of the parents’ stress by providing support while the child is 
in hospital. The Case Manager attends medical rounds with 
the doctors and is trained to re-explain the procedures and 
side effects of the medicine to the parents as well as bring 
questions from the parents back to the doctors. They can also 
assist with learning the hospital culture and how to man-
age the hospital system, including expectations for billing. 
The authors found that parents who worried about hospital 
expenses exceeding their means were more likely to abscond 
with their child before completing the course of treatment. 
In addition, the Case Manager contacts parents and reminds 
them of their child’s outpatient clinic appointments after dis-
charge and of the available transport reimbursement, which 
can improve follow-up care. While financial considerations 
are the major cause of treatment abandonment, insufficient 
communication between health providers and families 
can also contribute. In some cases, families stop treatment 
and abscond with early improvement in symptoms due to 
perceptions that the child is cured. In other cases, abandon-
ment may be related to premature lost hope. Thus, efforts 
should be made throughout the child’s hospitalization to 
explore guardians’ perceptions of the patient’s illness and 
offer counseling on their child’s diagnosis and prognosis, 
as well as the duration and goals of treatment, particularly 
given the low awareness of pediatric cancer in the commu-
nity and often limited knowledge of cancer as a potentially 
curable disease. Although there remains considerable focus 
on developing optimal chemotherapeutic regimens catered 
to individual patients, gains in survival will be limited until 
many of these additional factors known to influence adher-
ence to care are addressed.
Finally, a cancer diagnosis in a child often leads to a 
variety of physical, social, and emotional challenges for the 
child, as well as their families. In addition to the financial 
issues previously discussed, families can face social stigma 
and isolation, shifting household responsibilities, and loss 
of employment, among other issues. Many groups have 
worked to address these issues by providing family and 
psychosocial support through a multidisciplinary approach 
involving pediatric hematologists/oncologists, pediatricians, 
pharmacists, and nurses, as well as local nongovernmental 
organizations and the community. Creating a community with 
parent and survivor support groups provides a platform for 
advocacy and broader engagement.
The role of host genetics in contributing to eBL risk, as 
well as treatment response, remains unclear at this time and 
deserves further investigation. An appropriately powered 
and controlled genetic epidemiologic study has yet to be 
done; however, with the affordability of next generation 
sequencing, molecular risk stratification, and the formation 
of a BL research and clinical trial network, such studies are 
on the horizon.
Secondary complications
Treatment-related toxicity remains a major barrier to improv-
ing survival among children with BL. The most common 
toxicity of chemotherapy regimens that are used to treat BL is 
myelosuppression, which results in an increased susceptibil-
ity to infection. While this is a risk of many chemotherapeu-
tics in any setting, it is of particular concern in low-income 
settings where the ability to support patients through periods 
of neutropenia are limited. Compounding this issue is the fact 
that overcrowding is common in many hospitals in equatorial 
Africa because of the few locations where childhood cancer 
can be treated.4 Consequently, it is not unusual for children 
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with neutropenia to be on the same ward (or worse, in the 
same bed) as a child with a communicable disease, making 
transmission of infections to the neutropenic patient even 
more likely. Chemotherapy-induced myelosuppression may 
also cause anemia and/or thrombocytopenia. While this 
toxicity can be easily supported in high-income settings 
through transfusion center services, the same is not true for 
most low-income settings where access to safe blood products 
may be neither reliable nor timely.
Chemotherapy-induced nausea and vomiting is another 
factor to consider when discerning an appropriate treatment 
protocol for a given setting. In resource-rich environ-
ments, malnutrition is a problem rarely encountered, and 
supportive antiemetics along with enteral or parenteral 
nutrition (if needed) are readily available. However, in 
low-income countries where many children are malnour-
ished at baseline, the added challenge of chemotherapy-
induced nausea and vomiting can make a difficult problem 
worse. Lack of reliable access to antiemetics may result 
in worsening malnourishment following chemotherapy 
administration. Furthermore, access to nasogastric tubes 
or enteral/parenteral formulas may be scarce or completely 
inaccessible.
Other chemotherapy-associated toxicities that are less 
common but deserve consideration when determining opti-
mal treatment protocols include:
•	 mucositis (sometimes with lack of adequate analgesia), 
further complicating malnutrition
•	 skin necrosis from chemotherapy infiltration (when che-
motherapy is peripherally administered)
•	 nephrotoxicity from cyclophosphamide and methotrexate
•	 vincristine-induced peripheral neuropathy
•	 cardiomyopathy from anthracyclines
•	 risk of secondary malignancy associated with use of 
alkylating agents and etoposide
•	 chemotherapy impact on pre-existing comorbidities 
(eg, HIV management).
Conclusion: the way forward
Over the past 10 years, BL treatment for African children 
has received renewed attention within the global commu-
nity. During this period, the understanding of treatment 
regimens has evolved and appreciable progress has been 
made, from the single agent trials to the more intensive 
multidrug regimens that are more common today. Despite 
considerable investment in evaluating BL treatment options, 
clinical outcomes in many facilities in resource-limited 
settings remain suboptimal. Treatment-related mortality, 
late-stage of presentation, refusal of treatment, and aban-
donment of care remain major barriers to improving survival 
among children with eBL. Addressing these challenges is 
difficult, particularly in much of equatorial Africa where 
cancer care may not be as high priority as fighting acute 
infectious diseases and there continues to be a need for 
more basic, affordable health interventions. Formulating 
a BL treatment regimen should be made following a criti-
cal assessment of available resources and a strategic plan 
aimed at improving local conditions and increasing oncol-
ogy specialized training in order to meet a basic standard 
of care upon which one can build. Careful attention should 
be paid to offering treatment with intensity matching the 
level of ancillary support available, including infrastructure 
and capacity to offer routine antibiotics, blood products, 
and nutritional support. However, optimal management of 
BL requires more than just delivering chemotherapy and 
supportive care; there is a need to develop and implement 
improved paradigms of care delivery, ones that incorporate 
multidisciplinary strategies to more effectively address 
social, economic, and system level factors influencing care. 
Survival outcomes will only improve with increased access 
to care, more timely and accurate diagnoses, referral and 
initiation of treatment, and provision of robust social sup-
port to ameliorate many of the socioeconomic factors that 
can lead to refusal or abandonment of care. Complementing 
these efforts will be the application of empirical evidence 
arising from projects, such as the Cancer Genome Atlas,64 
that promise to elucidate biological pathways that can be 
targeted for the development of new and preferably less 
toxic chemotherapies used to cure BL.
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